Effect of a novel octapeptide urokinase fragment, A°6, on experimental choroidal neovascularization in the monkey

Retina

Volumn 26, Issue 2, 2006, Pages 202-209

  Koh, Hyoung J ^a,b   Freeman, William R ^a   Azen, Stanley P ^c   Flaxel, Christina J ^c   Labree, Laurie D ^c   Cheng, Linguen ^a   Wills, Margaret ^d   Jones, Terence R ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHARLES RIVER LABORATORIES   (United States)

^e Angstrom Pharmaceuticals   (United States)

Author keywords

Age related macular degeneration; Angiogenesis; Animal model; Choroidal neovascularization

Indexed keywords

OCTAPEPTIDE UROKINASE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG; UROKINASE; ACETYL LYSYL PROLYL SERYL SERYL PROLYL PROLYL GLUTAMYL GLUTAMIC ACID AMIDE; ACETYL-LYSYL-PROLYL-SERYL-SERYL-PROLYL-PROLYL-GLUTAMYL-GLUTAMIC ACID AMIDE; ANGIOGENESIS INHIBITOR; EYE DROPS; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; FEMALE; FLUORESCENCE ANGIOGRAPHY; LASER SURGERY; MONKEY; NONHUMAN; OPHTHALMOSCOPY; PATHOPHYSIOLOGY; PHOTOGRAPHY; SUBRETINAL NEOVASCULARIZATION; ANIMAL; DISEASE MODEL; INJECTION; MACACA; PATHOLOGY; RETREATMENT; TREATMENT OUTCOME; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; INJECTIONS; MACACA FASCICULARIS; OPHTHALMIC SOLUTIONS; PEPTIDE FRAGMENTS; RETREATMENT; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR; VITREOUS BODY;

EID: 33645741867     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200602000-00014     Document Type: Article

References (50)

1. Ferris III, FL Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642.
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-943.
3. The Eye Disease-Case Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 1992;110:1701-1708.
4. Moisseiev J, Alhalel A, Masuri R, Treister G. The impact of the macula photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch Ophthalmol 1995;113:185-189.
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003;136:407-418.
6. Mandal N, Chisholm IH. Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne). Br J Ophthalmol 2002;86:118-119.
7. American Academy of Ophthalmology. Macular translocation. Ophthalmology 2000;107:1015-1018.
8. Csaky K. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls. Ophthalmology 2003;110:879-881.
9. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal n fragment. Arch Ophthalmol 2002;120:338-346.
10. The Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-152.
11. Kvanta A, Shen WY, Sarman S, Seregard S, Steen B, Rakoczy E. Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization. Curr Eye Res 2000;21:684-690.
12. Takahashi T, Nakamura T, Hayashi A, et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelial cells. Am J Ophthalmol 2000;130:774-781.
13. Ozerdem U, Mach-Hofacre B, Cheng L, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res 2000;20:447-453.
14. Cheng L, Rivero ME, Garcia CR, et al. Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J Ocul Pharmacol Ther 2001;17:295-304.
15. Garcia C, Bartsch DU, Rivero ME, et al. Efficacy of prinomastat (AG3340), a matrix metalloproteinase inhibitor, in treatment of retinal neovascularization. Curr Eye Res 2002;24:33-38.
16. Ozerdem U, Mach-Hofacre B, Varki N, et al. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model. Curr Eye Res 2002;24:86-91.
17. Behzadian MA, Windsor LJ, Ghaly N, Liou G, Tsai NT, Caldwell RB. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 2003;17:752-754.
18. Hackett SF, Campochiaro PA. Modulation of plasminogen activator inhibitor-1 and urokinase in retinal pigmented endothelial cells. Invest Ophthalmol Vis Sci 1993;34:2055-2061.
19. Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR. Vascular endothelial growth factor (VEGF) induces rapid pro-urokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004;103:955-962.
20. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986;83:7297-7301.
21. Mignatti P, Mazzieri R, Rifkin DB. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol 1991;113:1193-1201.
22. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, Vassalli JD. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 1993;122:673-684.
23. Gualandris A, Presta M. Transcriptional and posttranslational regulation of urokinase-type plasminogen activator expression in endothelial cells by basic fibroblast growth factor. J Cell Physiol 1995;162:400-409.
24. Siconolfi LB, Seeds NW. Mice lacking tissue plasminogen activator and uroplasminogen activator genes show attenuated matrix metalloproteases activity after sciatic nerve crush. J Neurosci Res 2003;74:430-434.
25. Baramova EN, Bajou K, Remacle A, et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997;405:157-162.
26. Zhou HM, Nichols A, Meda P, Vassalli JD. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 2000;19:4817-4826.
27. Mazzieri R, Masiero L, Zanetta L, et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 1997;16:2319-2332.
28. Elner SG. Human retinal pigment epithelial lysis of extracellular matrix: functional urokinase plasminogen activator receptor, collagenase, and elastase. Trans Am Ophthalmol Soc 2002;100:273-299.
29. Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999;40:809-813.
30. Sirén V, Immonen I. uPA, tPA and PAI-1 mRNA expression in periretinal membranes. Curr Eye Res 2003;27:261-267.
31. Rakic JM, Lambert V, Munaut C, et al. Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:1732-1739.
32. McGuire PG, Jones TR, Talarico N, Warren E, Das A. The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A°6 suggests a new therapeutic target. Invest Ophthalmol Vis Sci 2003;44:2736-2742.
33. Koh HJ, Bessho K, Cheng L, et al. Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A°6. Invest Ophthalmol Vis Sci 2004;45:635-640.
34. Das A, Boyd N, Jones TR, Talarico N, McGuire PG. A peptide inhibitor of the urokinase/urokinase receptor system, A°6, inhibits choroidal neovascularization in a mouse model. Arch Ophthalmol (in press).
35. Cheng L, Hostetler KY, Chaidhawangul S, et al. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-o-hexadecylpro-panediol-3-phosphoganciclovir. Invest Ophthalmol Vis Sci 2002;43:515-521.
36. Miller H, Miller B, Ryan SJ. Correlation of choroidal subretinal neovascularization with fluorescein angiography. Am J Ophthalmol 1985;99:263-271.
37. Miller H, Miller B, Ryan SJ. The role of retinal pigment epithelium in the involution of subretinal neovascularization. Invest Ophthalmol Vis Sci 1986;27:1644-1652.
38. Shen WY, Garrett KL, Wang CG, et al. Preclinical evaluation of a phosphorothioate oligonucleotide in the retina of rhesus monkey. Lab Invest 2002;82:167-182.
39. Institute of Laboratory Animal Resources Commission on Life Sciences. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press; 1996.
40. Ohkuma H, Ryan SJ. Experimental subretinal neovascularization in the monkey. Permeability of new vessels. Arch Ophthalmol 1983;101:1102-1110.
41. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-346.
42. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
43. Koh HJ, Cheng L, Bessho K, Jones TR, Davidson MC, Freeman WR. Intraocular properties of urokinase-derived anti-angiogenic A6 peptide in rabbits. J Ocular Pharmacol Ther 2004;20:439-449.
44. Devy L, Blacher S, Grignet-Debrus C, et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002;16:147-154.
45. Lambert V, Munaut C, Carmeliet P, et al. Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. Invest Ophthalmol Vis Sci 2003;44:2791-2797.
46. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23:14-23.
47. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003;110:2372-2383.
48. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-745.
49. FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 2003;361:542-544.
50. Calabrese EJ. Estrogen and related compounds: biphasic dose responses. Crit Rev Toxicol 2001;31:503-515.